Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City
Zhongshan People's Hospital, Guangdong, China
40,000 participants
Apr 1, 2020
OBSERVATIONAL
Conditions
Summary
All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.
Eligibility
Inclusion Criteria5
- Subject residents in Zhongshan City or Wuzhou City
- Subject has no medical record of nasopharyngeal carcinoma
- ECOG 0-2
- Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
- Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study.
Exclusion Criteria2
- Subject has heavy cardiovascular, liver or kidney disease.
- Subject has contraindications to nasopharyngeal fiberoptic endoscopy.
Interventions
Collect blood and saliva samples from participants
Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
Screening participants will refer to fiberoptic endoscopy and biospy
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04085900